First update of the Lebanese guidelines for osteoporosis assessment and treatment
- PMID: 18782973
First update of the Lebanese guidelines for osteoporosis assessment and treatment
Abstract
With the ageing of the population worldwide, the human, social and economic costs of osteoporosis will continue to rise. It is estimated that the magnitude of the problem is larger in developing countries, including those in the Middle East. In April 2002, a multidisciplinary panel of experts met and discussed practice guidelines for osteoporosis assessment and treatment in Lebanon: "Who to test, what measures to use, and when to treat ?" They were subsequently endorsed by the Lebanese scientific societies of Endocrinology, Rheumatology, Orthopedics, Obstetrics & Gynecology, Radiology and by the Eastern Mediterranean Regional Office (EMRO), branch of the World Health Organization (WHO). In April 2006, the Guidelines Committee and the Lebanese Society for Osteoporosis and Metabolic Bone Disorders (OSTEOS) led an initiative to update several recommendations detailed in the original guidelines document, based on relevant new local and international data. Revisited guidelines included recommendations regarding the normative database to be used, the specific skeletal sites to be evaluated, recommendations in men and recommendations in premenopausal women. The experts also sought an evaluation of the relevance of the specific risk factors, used in the WHO fracture risk assessment model, to fracture risk assessment in the Lebanese. The purpose of the update of the guidelines was to reevaluate the rationale for the recommendations using further evidence when available and to position the Lebanese Osteoporosis Guidelines in relation to the WHO initiative for global fracture risk assessment.
Similar articles
-
First update of the Lebanese guidelines for osteoporosis assessment and treatment.J Clin Densitom. 2008 Jul-Sep;11(3):383-96. doi: 10.1016/j.jocd.2008.02.006. Epub 2008 May 2. J Clin Densitom. 2008. PMID: 18448373
-
Lebanese guidelines for osteoporosis assessment and treatment: who to test? What measures to use? When to treat?J Clin Densitom. 2005 Summer;8(2):148-63. doi: 10.1385/jcd:8:2:148. J Clin Densitom. 2005. PMID: 15908702
-
Vertebral fracture risk and impact of database selection on identifying elderly Lebanese with osteoporosis.Bone. 2007 Apr;40(4):1066-72. doi: 10.1016/j.bone.2006.11.016. Epub 2007 Jan 22. Bone. 2007. PMID: 17236834
-
[Absolute risk for fracture and WHO guideline. Fracture risk assessments recommended by World Health Organization and Japanese guidelines for prevention and treatment of osteoporosis 2006].Clin Calcium. 2007 Jul;17(7):1022-8. Clin Calcium. 2007. PMID: 17607068 Review. Japanese.
-
How to decide who to treat.Best Pract Res Clin Rheumatol. 2009 Dec;23(6):711-26. doi: 10.1016/j.berh.2009.09.002. Best Pract Res Clin Rheumatol. 2009. PMID: 19945684 Review.
Cited by
-
Nonpharmacological interventions for osteoporosis treatment: Systematic review of clinical practice guidelines.Osteoporos Sarcopenia. 2019 Sep;5(3):69-77. doi: 10.1016/j.afos.2019.09.005. Epub 2019 Oct 4. Osteoporos Sarcopenia. 2019. PMID: 31728423 Free PMC article. Review.
-
The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model.Osteoporos Int. 2017 Jan;28(1):127-137. doi: 10.1007/s00198-016-3766-5. Epub 2016 Sep 20. Osteoporos Int. 2017. PMID: 27650643
-
Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.Rheumatol Int. 2018 Dec;38(12):2193-2208. doi: 10.1007/s00296-018-4181-3. Epub 2018 Oct 26. Rheumatol Int. 2018. PMID: 30367203 Review.
MeSH terms
LinkOut - more resources
Medical
Miscellaneous